Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Conditions: Herpes Zoster; Shingles Interventions: Biological: CRV-101 Vaccine Antigen High Dose; Biological: CRV-101 Vaccine Antigen Low Dose; Biological: Shingrix Sponsors: Curevo Inc; Mogam Biotechnology Research Institute; Green Cross Corporation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Herpes | Research | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine